Here are the S-1 registration statements from GlucoTrack Inc New (GCTK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Glucotrack, Inc. (GCTK) registered up to 43,223,705 shares of common stock for resale, including shares issuable under warrants and convertible notes, Bridge Penalty Shares, and an equity-line arrangement. The prospectus says these registered shares represent approximately 1,825% of the 2,368,237 common shares outstanding as of October 5, 2026. Glucotrack is not selling shares through selling-stockholder resales and will receive no proceeds from those resales.
Under the ELOC Purchase Agreement, Glucotrack may direct purchases of up to $50.0 million of shares over three years, after the registration statement is declared effective and other conditions are satisfied. It must transfer 50% of proceeds from Purchase Share sales to Glucotrack Technologies to the extent legally available; remaining proceeds are for working capital and general corporate purposes. The company may also receive up to approximately $4.0 million from cash exercise of Interim PIPE warrants and up to approximately $33.3 million from cash exercise of September and PA Warrants. The auditor’s report expressed substantial doubt about its ability to continue as a going concern; cash and cash equivalents were approximately $3.9 million and accumulated deficit was approximately $156.2 million as of March 31, 2026.
Glucotrack, Inc. (GCTK) has filed a resale Form S-1 registering up to 43,447,017 shares of common stock for selling stockholders, largely tied to prior financings: bridge notes and warrants, an equity line of credit with White Lion Capital, an interim PIPE, and a September 2026 PIPE of secured convertible notes and warrants. Glucotrack is not selling shares in this offering but may separately sell up to $50 million of shares to the ELOC investor over three years, and could receive additional cash from warrant exercises.
The filing describes Glucotrack’s July 2026 business combination with Lokahi Therapeutics, leaving Lokahi (bee venom–based LT‑100 for inflammatory pain) and Glucotrack Technologies (implantable continuous blood glucose monitor) as operating subsidiaries. Former Lokahi holders received equity equal to 90% of fully diluted shares at closing.
The registered shares equal about 5,442% of the 798,390 shares outstanding on September 14, 2026, creating substantial potential resale overhang. The company discloses a history of net losses (accumulated deficit about $151.8 million) and a going‑concern warning, and details repeated Nasdaq compliance issues and a 1‑for‑15 reverse stock split effective August 28, 2026 to help maintain its Nasdaq Capital Market listing.